1-20 of 31
Robert L. Ferris
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit

Marco A. Mascarella, Tolani F. Olonisakin, Purva Rumde, Varun Vendra, Melonie A. Nance, Seungwon Kim, Mark W. Kubik, Shaum S. Sridharan, Robert L. Ferris, Moon J. Fenton, Daniel R. Clayburgh, James P. Ohr, Sonali C. Joyce, Malabika Sen, James G. Herman, Jennifer R. Grandis, Dan P. Zandberg, Umamaheswar Duvvuri
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 723–730.
https://doi.org/10.1158/1078-0432.CCR-22-1768
Published: 16 February 2023
View article titled, Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
Open the PDF for Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit in another window
Includes: Supplementary data
Journal Articles

Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes

Huaibin Ge, Robert L. Ferris, Jing H. Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (3): 647–658.
https://doi.org/10.1158/1078-0432.CCR-22-2355
Published: 01 February 2023
View article titled, Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
Open the PDF for Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer

Robert L. Ferris, Jessica Moskovitz, Sheryl Kunning, Ayana T. Ruffin, Carly Reeder, James Ohr, William E. Gooding, Seungwon Kim, Brian J. Karlovits, Dario A.A. Vignali, Umamaheswar Duvvuri, Jonas T. Johnson, Daniel Petro, Dwight E. Heron, David A. Clump, Tullia C. Bruno, Julie E. Bauman
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1335–1344.
https://doi.org/10.1158/1078-0432.CCR-21-0426
Published: 01 April 2022
View article titled, Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Open the PDF for Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer in another window
Journal Articles

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Bonnie S. Glisson, Rom S. Leidner, Robert L. Ferris, John Powderly, Naiyer A. Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James P. Ohr, Jennifer Burton, Yanan Zheng, Steven Eck, Matthew Gribbin, Katie Streicher, Danielle M. Townsley, Sandip Pravin Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5358–5367.
https://doi.org/10.1158/1078-0432.CCR-19-3070
Published: 15 October 2020
View article titled, Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract PR06: Tumor-infiltrating B cells colocalize with CD4 T effector cells within tertiary lymphoid structures to present antigen and educate the antitumor immune response in human primary tumors

Ayana T. Ruffin, Anthony R. Cillo, Sheryl Kunning, Robert L. Ferris, Dario A.A. Vignali, Tullia C. Bruno
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): PR06.
https://doi.org/10.1158/1557-3265.AACRAHNS19-PR06
Published: 15 June 2020
View article titled, Abstract PR06: Tumor-infiltrating B cells colocalize with CD4 T effector cells within tertiary lymphoid structures to present antigen and educate the antitumor immune response in human primary tumors
Journal Articles

Abstract PR05: APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma

Yan Lin, Shuyan Zhai, Fengshen Kuo, Timothy A. Chan, Luc G. Morris, Robert L. Ferris, Daniel L. Faden, Fei Ding
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): PR05.
https://doi.org/10.1158/1557-3265.AACRAHNS19-PR05
Published: 15 June 2020
View article titled, Abstract PR05: APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma
Journal Articles

Abstract A24: Multitiered assessment of the incidence and demographics of patients with multiple human papillomavirus-mediated head and neck cancers

William Strober, Burton Wood, Sachie Shishido, James Lewis, Krystle Kuhs, Robert L. Ferris, Daniel L. Faden
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): A24.
https://doi.org/10.1158/1557-3265.AACRAHNS19-A24
Published: 15 June 2020
View article titled, Abstract A24: Multitiered assessment of the incidence and demographics of patients with multiple human papillomavirus-mediated head and neck cancers
Journal Articles

Abstract PR03: The tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC): Investigating new aspects of known cell types using single-cell RNA sequencing

Cornelius Kürten, Aditi Kulkarni, Xueer Chen, Lazar Vujanovic, Anthony Cillo, Xinghua Lu, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): PR03.
https://doi.org/10.1158/1557-3265.AACRAHNS19-PR03
Published: 15 June 2020
View article titled, Abstract PR03: The tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC): Investigating new aspects of known cell types using single-cell RNA sequencing
Journal Articles

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Robert L. Ferris, Lisa Licitra, Jerome Fayette, Caroline Even, George Blumenschein, Jr, Kevin J. Harrington, Joel Guigay, Everett E. Vokes, Nabil F. Saba, Robert Haddad, Shanmugasundaram Ramkumar, Jeffery Russell, Peter Brossart, Makoto Tahara, A. Dimitrios Colevas, Fernando Concha-Benavente, Mark Lynch, Li Li, Maura L. Gillison
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (17): 5221–5230.
https://doi.org/10.1158/1078-0432.CCR-18-3944
Published: 03 September 2019
View article titled, Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Open the PDF for Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use in another window
Includes: Supplementary data
Journal Articles

Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients

Zhuqing Liu, Elizabeth L. McMichael, Gulidanna Shayan, Jing Li, Kevin Chen, Raghvendra Srivastava, Lawrence P. Kane, Binfeng Lu, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (18): 4529–4538.
https://doi.org/10.1158/1078-0432.CCR-17-1350
Published: 14 September 2018
View article titled, Novel Effector Phenotype of Tim-3<sup>+</sup> Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients
Open the PDF for Novel Effector Phenotype of Tim-3<sup>+</sup> Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine

Yee Sun Tan, Kanokwan Sansanaphongpricha, Yuying Xie, Christopher R. Donnelly, Xiaobo Luo, Blake R. Heath, Xinyi Zhao, Emily Bellile, Hongxiang Hu, Hongwei Chen, Peter J. Polverini, Qianming Chen, Simon Young, Thomas E. Carey, Jacques E. Nör, Robert L. Ferris, Gregory T. Wolf, Duxin Sun, Yu L. Lei
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17): 4242–4255.
https://doi.org/10.1158/1078-0432.CCR-17-2807
Published: 04 September 2018
View article titled, Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine
Open the PDF for Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

Gulidanna Shayan, Benjamin A. Kansy, Sandra P. Gibson, Raghvendra M. Srivastava, James Kyle Bryan, Julie E. Bauman, James Ohr, Seungwon Kim, Umamaheswar Duvvuri, David A. Clump, Dwight E. Heron, Jonas T. Johnson, Robert M. Hershberg, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 62–72.
https://doi.org/10.1158/1078-0432.CCR-17-0357
Published: 02 January 2018
View article titled, Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Open the PDF for Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals in another window
Includes: Supplementary data
Journal Articles

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer

Raghvendra M. Srivastava, Sumita Trivedi, Fernando Concha-Benavente, Sandra P. Gibson, Carly Reeder, Soldano Ferrone, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (3): 707–716.
https://doi.org/10.1158/1078-0432.CCR-16-0879
Published: 31 January 2017
View article titled, CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Open the PDF for CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients

Sumita Trivedi, Raghvendra M. Srivastava, Fernando Concha-Benavente, Soldano Ferrone, Tatiana M. Garcia-Bates, Jing Li, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5229–5237.
https://doi.org/10.1158/1078-0432.CCR-15-2971
Published: 31 October 2016
View article titled, Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Open the PDF for Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer

Neil D. Gross, Julie E. Bauman, William E. Gooding, William Denq, Sufi M. Thomas, Lin Wang, Simion Chiosea, Brian L. Hood, Melanie S. Flint, Mai Sun, Thomas P. Conrads, Robert L. Ferris, Jonas T. Johnson, Seungwon Kim, Athanassios Argiris, Lori Wirth, Marina N. Nikiforova, Jill M. Siegfried, Jennifer R. Grandis
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (12): 3289–3298.
https://doi.org/10.1158/1078-0432.CCR-13-3360
Published: 12 June 2014
View article titled, Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer
Open the PDF for Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

Patrick J. Schuler, Malgorzata Harasymczuk, Carmen Visus, Albert DeLeo, Sumita Trivedi, Yu Lei, Athanassios Argiris, William Gooding, Lisa H. Butterfield, Theresa L. Whiteside, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2433–2444.
https://doi.org/10.1158/1078-0432.CCR-13-2617
Published: 30 April 2014
View article titled, Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
Open the PDF for Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients

Raghvendra M. Srivastava, Steve C. Lee, Pedro A. Andrade Filho, Christopher A. Lord, Hyun-Bae Jie, H. Carter Davidson, Andrés López-Albaitero, Sandra P. Gibson, William E. Gooding, Soldano Ferrone, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1858–1872.
https://doi.org/10.1158/1078-0432.CCR-12-2426
Published: 02 April 2013
View article titled, Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Open the PDF for Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients in another window
Includes: Supplementary data
Journal Articles

The Immune Signature of CD8+CCR7+ T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC

Malgorzata Czystowska, William Gooding, Miroslaw J. Szczepanski, Andres Lopez-Abaitero, Robert L. Ferris, Jonas T. Johnson, Theresa L. Whiteside
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 889–899.
https://doi.org/10.1158/1078-0432.CCR-12-2191
Published: 14 February 2013
View article titled, The Immune Signature of CD8<sup>+</sup>CCR7<sup>+</sup> T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC
Open the PDF for The Immune Signature of CD8<sup>+</sup>CCR7<sup>+</sup> T Cells in the Peripheral Circulation Associates with Disease Recurrence in Patients with HNSCC in another window
Includes: Supplementary data
Journal Articles

SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells

Michael S. Leibowitz, Raghvendra M. Srivastava, Pedro A. Andrade Filho, Ann Marie Egloff, Lin Wang, Raja R. Seethala, Soldano Ferrone, Robert L. Ferris
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 798–808.
https://doi.org/10.1158/1078-0432.CCR-12-1517
Published: 14 February 2013
View article titled, SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells
Open the PDF for SHP2 Is Overexpressed and Inhibits pSTAT1-Mediated APM Component Expression, T-cell Attracting Chemokine Secretion, and CTL Recognition in Head and Neck Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T Cells

Carmen Visus, Yangyang Wang, Antonio Lozano-Leon, Robert L. Ferris, Susan Silver, Miroslaw J. Szczepanski, Randall E. Brand, Cristina R. Ferrone, Theresa L. Whiteside, Soldano Ferrone, Albert B. DeLeo, Xinhui Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (19): 6174–6184.
https://doi.org/10.1158/1078-0432.CCR-11-1111
Published: 02 October 2011
View article titled, Targeting ALDH<sup>bright</sup> Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8<sup>+</sup> T Cells
Open the PDF for Targeting ALDH<sup>bright</sup> Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8<sup>+</sup> T Cells in another window
Includes: Supplementary data